scholarly journals Long-term treatment response on therapy trifluridin/tipiracil (Lonsurf®) in patient with metastatic colorectal cancer

Onkologie ◽  
2020 ◽  
Vol 14 (Suppl.D) ◽  
pp. 62-66
Author(s):  
Šárka Stuhlová
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Treatment Response ◽  
Term Treatment ◽  
Long Term Treatment

INFLUENCE OF THE AGE FACTOR AND TUMOR IMMUNOPHENOTYPE ON THE EFFECTIVENESS OF CYTOREDUCTIVE OPERATIONS IN METASTATIC COLORECTAL CANCER

2019 ◽  
Vol 65 (6) ◽  
pp. 855-862
Author(s):  
Nikolay Maystrenko ◽  
Georgiy Manikhas ◽  
Aleksey Sazonov ◽  
Vadim Chirskiy ◽  
Alina Yerokhina
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Significant Risk ◽  
Biological Properties ◽  
Term Treatment ◽  
Ki 67 ◽  
Immunohistochemical Markers ◽  
Long Term Treatment ◽  
Age Factor

Aim of the study. To analyze the effectiveness and safety of cytoreductive interventions in patients with IV stage colorectal cancer in account of the age factor and to assess the effect of the molecular biological properties of the tumor on long-term treatment results. Materials and methods. A comparative evaluation of the results of surgical treatment of metastatic colorectal cancer in patients of various age groups was carried out. The clinical significance of immunohistochemical markers for predicting long-term treatment outcomes has been studied. Results. The most significant risk factors for the development of postoperative complications were identified. The prognostic value of immunohistochemical markers such as the proliferative index of stem cancer cells (ALDH + Ki-67 +) and the chemokine receptor CXCR4 has been established. Conclusion. A comprehensive analysis of the molecular biological properties of the tumor, coupled with an assessment of the functional operability of patients, provides a personalized approach to the choice of surgical tactics in patients with stage IV colorectal cancer, which allows counting on the encouraging results of cytoreductive interventions.

scholarly journals Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab

2012 ◽  
Vol 6 ◽  
pp. CMO.S5055 ◽  
Author(s):  
Miriam López-Gómez ◽  
María Merino ◽  
Enrique Casado
Keyword(s):  
Colorectal Cancer ◽  
Monoclonal Antibody ◽  
Metastatic Colorectal Cancer ◽  
Systemic Chemotherapy ◽  
Term Treatment ◽  
Long Term Treatment

Colorectal cancer is one of the leading causes of cancer-related deaths worldwide. More than 30% patients present with metastases at diagnoses and will require systemic chemotherapy. In recent years many anti-EGFR targets have been developed. Among them, panitumumab, a fully human IgG2 monoclonal antibody has shown important benefits in the treatment of this disease.

Fluvoxamine in the Treatment of Trichotillomania: An 8-Week, Open-Label Study

CNS Spectrums ◽  
1998 ◽  
Vol 3 (9) ◽  
pp. 64-71 ◽  
Author(s):  
Gary A. Christenson ◽  
Scott J. Crow ◽  
James E. Mitchell ◽  
Thomas B. Mackenzie ◽  
Ross D. Crosby ◽  
...  
Keyword(s):  
Treatment Response ◽  
Term Treatment ◽  
Hair Pulling ◽  
Short Term ◽  
Open Label ◽  
Short Term Treatment ◽  
Open Label Study ◽  
Label Study ◽  
Long Term Treatment

AbstractThis short-term, open-label study investigates short- and long-term effects of the selective serotonin reuptake inhibitor (SSRI) fluvoxamine for the treatment of trichotillomania (TTM). Additionally, this study aimed to test the hypothesis that the presence of hair pulling compulsiveness is predictive of SSRI response. Nineteen subjects meeting the Diagnostic and Statistical Manual of Mental Disorders, Third Edition Revised, (DSM-III-R) criteria for TTM were treated with fluvoxamine at doses up to 300 mg/day. Random regression analysis of change across time for patients who completed the study (n=14) and those who dropped out (n=5) revealed statistically significant improvements in Physician Rating Scale, hair-pulling episodes, Trichotillomania Impairment Scale, and Trichotillomania Symptom Severity Scale, but not in estimated amount of hair pulled. In addition, the percentage of patients' focused or compulsive hair-pulling symptoms was predictive of treatment response. Unfortunately, all three subjects who entered long-term treatment displayed substantial movement back toward baseline by the end of 6 months. We concluded that fluvoxamine produces moderate reductions in symptoms during the short-term treatment of TTM and that the presence of focused or compulsive hair pulling may be predictive of treatment response. However, responses may be short lived when treatment is extended.

Sign in / Sign up

Export Citation Format

Share Document